PT  - JOURNAL ARTICLE
AU  - Abebe, Abnet
AU  - Bouyssou, Isabelle
AU  - Mabilotte, Solenne
AU  - Dugassa, Sisay
AU  - Assefa, Ashenafi
AU  - Juliano, Jonathan J.
AU  - Lo, Eugenia
AU  - Menard, Didier
AU  - Golassa, Lemu
TI  - Potential hidden <em>Plasmodium vivax</em> malaria reservoirs from low parasitemia Duffy-negative Ethiopians: molecular evidence
AID  - 10.1101/2023.04.24.23289013
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.24.23289013
4099  - http://medrxiv.org/content/early/2023/04/26/2023.04.24.23289013.short
4100  - http://medrxiv.org/content/early/2023/04/26/2023.04.24.23289013.full
AB  - Background The interaction between the Plasmodium vivax Duffy-binding protein and the corresponding Duffy Antigen Receptor for Chemokines (DARC) is primarily responsible for the invasion of reticulocytes by P. vivax. The Duffy-negative host phenotype, highly prevalent in sub-Saharan Africa, is caused by a single point mutation in the GATA-1 transcription factor binding site of the DARC gene promoter. The aim of this study was to assess the Duffy status of patients with P. vivax infection from different study sites in Ethiopia.Methods A cross-sectional study was conducted from February 2021 to September 2022 at five varying eco-epidemiological malaria endemic sites in Ethiopia. Outpatients who were diagnosed with P. vivax infection (pure and mixed P. vivax/P. falciparum) by microscopy were subjected to qPCR genotyping at the DARC promoter. The associations between P. vivax infection, host genotypes and other factors were evaluated.Result In total, 361 patients with P. vivax infection were included in the study. Patients with pure P. vivax infections accounted for 89.8% (324/361), while the remaining 10.2% (37/361) had mixed P. vivax/P. falciparum infections. About 95.6% (345/361) of the participants were Duffy-positives (21.2% homozygous and 78.8%, heterozygous) and 4.4% (16/361) were Duffy-negatives. The mean asexual parasite density in homozygous and heterozygous Duffy-positives was 12,165 p/µl (IQR25-75: 1,640-24,234 p/µl) and11,655 p/µl (IQR25-75: 1,676-14,065 p/µl), respectively, significantly higher than that in Duffy-negatives (1,227p/µl; IQR25-75: 539-1,732p/µl).Conclusion This study confirms that Duffy-negativity does not provide complete protection against P. vivax infection. The development of P. vivax-specific elimination strategies, including alternative antimalarial vaccines should be facilitated by a better understanding of the epidemiological landscape of vivax malaria in Africa. More importantly, low parasitemia associated with P. vivax infections in Duffy-negative patients may represent hidden reservoirs of transmission in Ethiopia.Author Summary Plasmodium vivax generally receives less attention than P. falciparum and was neglected in sub-Saharan Africa. However, the characteristics of P. vivax infection in Duffy-negative individuals, and the distribution of Duffy blood group in different eco-epidemiological zones and ethnic groups of Ethiopia are not well documented. Here, we determined the Duffy genotypes of P. vivax infected patients across broad regions of Ethiopia. It is clear that Duffy negative individuals in Ethiopia are not fully protected against P. vivax infection, and that these infections in Duffy negatives are often associated with low parasitemia. Our findings lend support to the notion that P. vivax may have developed a Duffy-independent erythrocyte invasion pathway and/or evolution in host immune responses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Aklilu Lemma Institute Pathobiology Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript. The data that support the findings of this study are available from the corresponding author on reasonable request.ALIPBAklilu Lema Institute of PathobiologyDARCDuffy antigen receptor for chemokinesDBPDuffy Binding ProteinDBSDried Blood SpotsDNADeoxyribonucleic AcidEPHIEthiopian Public Health InstituteHRPHistidine-rich proteinIRBInstitutional Review BoardMoEMinistry of EducationNSPNational Strategic PlanpLDHPlasmodium lactate dehydrogenasePv/PfPlasmodium vivax and Plasmodium falciparumRDTRapid Diagnostic TestsRT PCRReal Time Polymerase Chain ReactionSNPSingle Nucleotide PolymorphismSOPStandard Operating ProceduresSPSSStatistical Package for Social SciencesWBCWhite Blood CellsWHOWorld Health Organization